Hindawi Publishing Corporation Stem Cells International Article ID 421253 Research Article Alterations in the Secretome of Clinically Relevant Preparations of Adipose-Derived Mesenchymal Stem Cells Cocultured with Hyaluronan Peter Succar, 1,2 Edmond J. Breen, 3 Donald Kuah, 4 and Benjamin R. Herbert 2,5 1 Department of Chemistry and Biomolecular Sciences, Macquarie University, Oice 256, Building E8C, Balaclava Road, North Ryde, NSW 2109, Australia 2 Royal North Shore Hospital, University of Sydney, St Leonards, NSW 2065, Australia 3 Australian Proteome Analysis Facility, Macquarie University, North Ryde, NSW 2109, Australia 4 Sydney Sports Medicine Centre, 6 Figtree Drive, Sydney Olympic Park, NSW 2127, Australia 5 Regeneus Ltd., 25 Bridge Street, Pymble, NSW 2073, Australia Correspondence should be addressed to Benjamin R. Herbert; benjamin.herbert@sydney.edu.au Received 25 February 2015; Revised 10 June 2015; Accepted 11 June 2015 Academic Editor: Tong-Chuan He Copyright © Peter Succar et al. his is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Osteoarthritis (OA) can be a debilitating degenerative disease and is the most common form of arthritic disease. here is a general consensus that current nonsurgical therapies are insuicient for younger OA suferers who are not candidates for knee arthroplasties. Adipose-derived mesenchymal stem cells (MSCs) therapy for the treatment of OA can slow disease progression and lead to neocartilage formation. he mechanism of action is secretion driven. Current clinical preparations from adipose tissue for the treatment of OA include autologous stromal vascular fraction (SVF), SVF plus mature adipocytes, and culture-puriied MSCs. Herein we have combined these human adipose-derived preparations with Hyaluronan (Hylan G-F 20: Synvisc) in vitro and measured alterations in cytokine proile. SVF plus mature adipocytes showed the greatest decreased in the proinlammatory cytokines IL-1, IFN-, and VEGF. MCP-1 and MIP-1 decreased substantially in the SVF preparations but not the puriied MSCs. he puriied MSC preparation was the only one to show increase in MIF. Overall the SVF plus mature adipocytes preparation may be most suited of all the preparations for combination with HA for the treatment of OA, based on the alterations of heavily implicated cytokines in OA disease progression. his will require further validation using in vivo models. 1. Introduction Osteoarthritis (OA) can be a debilitating degenerative disease and is the most common form of arthritic disease. Onset is usually in the third and fourth decade of life and has a gradual worsening prognosis over time. OA is most prevalent in weight bearing joints; the highest incidence of the disease occurs in the knee. It is classiied as idiopathic and or secondary. Primary clinical interven- tion currently involves limited systemic pharmacotherapy such as analgesics and nonsteroidal anti-inlammatory drugs (NSAIDs). Controlling mechanical overload through weight loss and supporting braces can be used autonomously or in combination with physical therapy. Viscosupplementation can also be used to treat OA. his aims to replace lost synovial luid in an OA knee with Hyaluronan (HA) to reduce pain and increase mobility by lubricating the joint. HA is an endogenous polysaccharide found in all tissues and body luids of vertebrates. HA is especially abundant in loose connective tissue and is a major component of cartilage [1] and the synovium [2]. Aside from its rheological properties, high molecular weight HA can decrease apoptosis, oxidative stress, and necrosis [3]. Arthroscopic surgical interventions are used for the debridement of mechanical cartilage tears, lesions, and defects, as well as cartilage resurfacing or microfracture to